The stock may react positively to strong top-line growth and raised guidance, but investors should monitor gross margin trends and the pace of system placements. A key risk is whether the company can deliver on its margin improvement targets given recent cost pressures.
Price Chart
Executive Summary
Rapid Micro Biosystems reported strong revenue growth for Q4 and full-year 2025, with Q4 revenue up 37% YoY to $11.3 million and full-year revenue up 20% to $33.6 million, driven by a 78% surge in product sales. However, gross margins turned negative due to a $1.1 million inventory write-off, and the company maintained a significant net loss. Management raised 2026 revenue guidance to $37M–$41M and expects gross margins to improve to ~20%, signaling confidence in continued commercial momentum from recent wins with Amgen and Samsung Biologics.
Key Financial Metrics
Key Facts
- Q4 2025 revenue: $11.3 million (+37% YoY); full-year 2025 revenue: $33.6 million (+20% YoY)
- Product revenue grew 78% in Q4 to $9.3 million, but service revenue fell 34% to $2.0 million
- Gross margin was negative 3% in Q4 (vs. +12% in Q4 2024) due to $1.1 million inventory write-off
- Non-GAAP adjusted gross margin was 7% in Q4 and 6% for full-year 2025
- Net loss widened to $12.5 million in Q4 and $47.1 million for the year
- Company placed 16 systems in Q4 and 28 for the full year; 190 cumulative systems placed globally
- 2026 revenue guidance: $37.0M–$41.0M with ~20% gross margin and 30–38 system placements
Financial Impact
Revenue growth is strong, but profitability remains under pressure. The $1.1 million inventory write-off significantly impacted margins. 2026 guidance implies 10-22% revenue growth and meaningful margin expansion to ~20%.
Risk Factors
- Continued negative GAAP gross margins could pressure cash flow
- Reliance on large, lumpy system orders may lead to revenue volatility
- Execution risk in scaling manufacturing and service operations to support growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254470 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 7, 2026 11w ago | 8-K | $1.73 $1.31 | ▲ +24.28% | ▲ +23.88% | $0.7870 (+54.51%) |
Jul 23, 2026 13w ago | Press Release | $1.99 | awaiting T+20 | — | $0.7870 (−60.45%) |
May 19, 2026 23w ago | 424B5 | $2.01 $1.71 | ▲ +14.93% | ▲ +15.67% | $0.7870 (+60.85%) |
May 13, 2026 23w ago | 8-K | $2.32 $1.76 | ▲ +24.14% | ▲ +23.28% | $0.7870 (+66.08%) |
Apr 8, 2026 28w ago | DEFA14A | $2.12 $2.53 | ▲ +19.34% | ▲ +11.77% | $0.7870 (−62.88%) |
Mar 12, 2026 32w ago | 8-K | $3.43 $2.12 | ▼ −38.10% | ▼ −40.08% | $0.7870 (−77.02%) |
Mar 12, 2026 32w ago | Press Release | $3.43 $2.12 | ▼ −38.10% | ▼ −40.08% | $0.7870 (−77.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers